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We here report a case of association between primary biliary cirrhosis and anti-synthetase
syndrome with exclusive interstitial lung involvement. The patient developed exertional
dyspnoea 14 years after being diagnosed with primary biliary cirrhosis. Search for auto-
antibodies showed positivity for anti-Jo-1. No clinically evident myositis was present.
HRCT scan showed bilateral interstitial pulmonary involvement, and the BAL yielded an
alveolar lymphocytosis with low CD4/CD8 ratio. Treatment with systemic corticosteroids
led to rapid improvement of the clinico-radiological picture. Although primary biliary
cirrhosis had been previously found in association with polymyositis, no previous reports of
its association with anti-Jo-1 syndrome with prominent pulmonary involvement are known.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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A 73-year-old female, non-smoker, with diabetes mellitus,
no history of allergies, no significant occupational expo-
sures, was admitted to the hospital in October 2006 for
evaluation of progressive exertional dyspnoea. She had been
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Figure 2 Control chest HRCT scan taken in the prone position,
7 month after beginning of steroidal treatment: complete
resolution of the interstitial infiltrates and of the ground-glass
opacities.
M. D’Avanzo et al.52diagnosed with primary biliary cirrhosis (PBC) in 1991
based on liver biopsy and presence of serum anti-mitochon-
drial antibodies. In 1990, she had been treated surgically
(hemicolectomy) for colonic cancer. She had no fever
and no joint or muscle pain. Raynaud’s phenomenon was
absent. Muscle strength was normal. No skin lesions were
present. The chest examination revealed basal bilateral
crackles.
Laboratory tests showed normal hemogram, increased
alkaline phosphatase (506 UI/mL), gamma-glutamyl trans-
ferase (259UI/mL) and total cholesterol (232mg/dL).
Creatine phosphokinase was not elevated. Positivity for
HBs antibody and HBc antibody was detected, indicating
previous Hepatitis B infection. The patient also tested
positive for the homozygous H63D mutation of the hemo-
chromatosis gene (HFE), but blood iron and ferritin were not
altered. Search for autoantibodies showed positivity for
anti-Jo-1 and anti-SS-A/R0. High resolution CT scan of the
chest showed reticular opacities and ground-glass areas
mainly localized in both upper lobes, consistent with a non-
specific interstitial pneumonia (NSIP) pattern (Figure 1).
Lung function tests Figure 2 showed mild restrictive deficit
(forced vital capacity (FVC) 71% of predicted value, forced
expiratory volume in 1 s (FEV1) 81% of predicted, FEV1/FVC%
80), with reduced lung transfer factor for CO (TLCO 57%
of predicted value). Low arterial oxygen saturation was
detected at rest (85%), requiring oxygen therapy (2 L/min).
Bronchoalveolar lavage (BAL) was then performed, yielding
a lymphocytic inflammation, with a low CD4/CD8 ratio. Due
to the presence of respiratory failure a decision was made
not to proceed with a lung biopsy, and to immediately start
treatment with prednisone (0.5mg/kg/day). The therapy
led to gradual improvement of symptoms. Simultaneously,
therapy with ursodeoxycholic acid (600mg twice daily) wasFigure 1 Chest HRCT scan taken with the patient in the prone
position (due to marked dyspnoea) before the beginning of
corticosteroidal treatment: diffuse bilateral thickening of the
interstitial septa, more marked at the lung periphery, asso-
ciated with ground-glass opacities with lobular distribution.begun, as the patient had never been treated before for
PBC, resulting in a marked improvement of the cholestasis
indices. High-resolution computed tomography (HRCT) scan
performed 7 months after the diagnosis showed almost
complete resolution of the reticular pattern and marked
reduction of ground-glass opacities (Figure 1). In light of the
significant clinical and functional improvement it was
possible to discontinue the oxygen therapy and to reduce
the dose of prednisone to 0.25mg/kg/day, and the condi-
tions of the patient have remained stable up to now.Discussion
The anti-synthetase syndrome (AAS) is a relatively uncom-
mon clinical entity of autoimmune nature, found more
frequently in adult female patients, and characterized by
positivity to serum antibodies directed against aminoacyl-
tRNA synthetases and a variable combination of myositis,
interstitial pneumonia, arthritis, Raynaud’s phenomenon,
mechanic’s hands.1 This condition is considered a subset of
idiopathic inflammatory myopathies. There have been rare
reports of AAS cases in which the lung involvement was the
main, sometimes exclusive, manifestation at the onset.2
Among the anti-synthetase antibodies more frequently
associated with lung involvement the anti-Jo-1 is one of
the better known. It is noteworthy that, when present, the
lung disease is the main determinant of survival in patients
with AAS. In the present case study, we report the
association of PBC and anti-Jo-1 syndrome with predominant
interstitial lung disease. To our knowledge, such an
association has not been reported before, although there
are few documented cases of PBC associated with poly-
miositis with typical muscle involvement and no lung
disease.3 The chest HRCT in our case showed a NSIP pattern,
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Anti-synthetase syndrome with lung involvement associated with primary biliary cirrhosis 53and, while not confirmed bioptically in our case, this finding
is consistent with the observed, prompt response to
corticosteroids which is typical of this type of interstitial
lung disease. Moreover, among the patterns of interstitial
pneumonia found in association with polymyositis, NSIP is
relatively common. In our patient, the pattern of pulmonary
inflammation as evidenced by the BAL was consistent with
previous reports of lung disease in AAS (2), as it presented
mainly a lymphocytosis with low CD4/CD8 ratio. Although
the main features of lung involvement in our patient did not
differ from previously described cases of AAS, a potential
role of the coexisting PBC in the pathogenesis of lung disease
cannot be excluded: PBC itself has been found in association
with a spectrum of pulmonary abnormalities, from sub-
clinical alveolar lymphocytosis to interstitial fibrosis,4,5
although a definite interstitial pneumonia has been reported
only rarely in PBC patients. We conclude that the presence
of anti-synthetase and anti-mitochondrial antibodies should
be always tested, among other auto-antibodies, in all
patients who develop interstitial lung disease in absence
of known causes of pulmonary fibrosis.Conflict of interest statement
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References
1. Imbert-Masseau A, Hamidou M, Agard C, Grolleau JY, Cherin P.
Antysynthetase syndrome. Joint Bone Spine 2003;70(3):161–8.
2. Sauty A, Rochat T, Schoch OD, et al. Pulmonary fibrosis with
predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibo-
dies. Eur Respir J 1997;10:2907–12.
3. Yasuda Y, Nakano N, Akiguchi I, Tanaka M, Kameyama M.
Polymyositis associated with asymptomatic primary biliary
cirrhosis. Eur Neurol 1993;33(1):51–3.
4. Wallaert B, Bonniere P, Prin L, Cortot A, Tonnel AB, Voisin C.
Primary biliary cirrhosis. Subclinical inflammatory alveolitis in
patients with normal chest roentgenograms. Chest 1986;90(6):
842–8.
5. Hiraoka A, Kojima N, Yamauchi Y, et al. An autopsy case of
primary biliary cirrhosis with severe interstitial pneumonia.
Intern Med 2001;40(11):1104–8.
